NCT02920697 - Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 22, 2018

Study Completion Date

October 22, 2018

Conditions

Chronic Lymphocytic Leukaemia (CLL)B-Cell Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)

Interventions

DRUG

S 55746

S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.

Trial Locations (18)

3004

The Alfred Hospital Malignant Haematology & Stem Cell Transplantation Services, Melbourne

Unknown

Hopital Claude Huriez, Lille

CHU de Nantes, Nantes

Centre hospitalier Lyon Sud, Pierre-Bénite

Gustave Roussy, Villejuif

Universitätsklinikum Carl Gustav Carus, Dresden

Städtisches Klinikum Schwabing, Munich

Universitätsklinikum Ulm, Ulm

National Oncology Institute, Budapest

CRU Hungary Kft, Miskolc

Warsaw Institute of Oncology, Warsaw

Warsaw Medical University, Warsaw

National Cancer Center (NCC), Singapore

National University Cancer Institute Singapore, Singapore

Severance Hospital, Seoul

St. Mary's Hospital, Seoul

University College London Hospitals, London

Freeman Hospital, Newcastle

All Listed Sponsors

collaborator

ADIR, a Servier Group company

INDUSTRY

lead

Institut de Recherches Internationales Servier

OTHER